Lieberman Publishes Findings in Clinical Trials
Pediatric nephrology chief publishes on rare kidney diseases
Kenneth Lieberman, M.D., chief of Pediatric Nephrology at Joseph M. Sanzari Children’s Hospital, has published findings in several ongoing clinical trials for children and young adults with kidney disease. Dr. Lieberman is a pioneer in the use of genetics to diagnose kidney disease and an expert in the treatment of many kidney conditions.
Pediatric nephrology researchers at Hackensack Meridian Children’s Health — which is ranked No. 34 in the nation for pediatric nephrology by U.S. News & World Report — are participating in four medication clinical trials for children and young adults with rare kidney disease.
A variety of international, multicenter trials have been offered at Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center and provide young patients with access to promising treatments years before they become widely available. Clinical trials include:
VALIANT trial. Joseph M. Sanzari Children’s Hospital is currently the only site in New Jersey offering this study, which aims to determine the effectiveness of subcutaneously infused medication pegcetacoplan when compared to placebo in reducing high levels of protein in the urine. The trial is open to patients aged 12 years and older with C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.
COMMUTE-p trial. This study aims to study the effectiveness of the intravenous medication Crovalimab in pediatric patients with atypical hemolytic uremic syndrome. Joseph M. Sanzari Children’s Hospital is currently the only site in New Jersey to offer this clinical trial.
VX-147 trial. This study will evaluate the safety, efficacy, tolerability, and pharmacokinetics of oral medication VX-147 in patients aged 18 and older with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
As a network, Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center and K. Hovnanian Children’s Hospital at Jersey Shore University Medical Center, are leaders in research breakthroughs, and the treatment and diagnosis of rare pediatric kidney conditions.
about our advancements in pediatric nephrology.
